Sarepta receives FDA decision deadline for exon-skipping therapies, appoints Anna Protopapas as Flare CEO
read at Endpoints ↗RegulatoryNeutral
The U.S. Food and Drug Administration has set a deadline for a decision on Sarepta Therapeutics' exon‑skipping drug program, with the agency expected to rule by the end of February.
The timing is critical for Sarepta, as the outcome will determine whether its next‑generation treatments for muscular dystrophy can move forward toward market approval.
In related news, Flare Therapeutics announced the appointment of Anna Protopapas as its new chief executive officer, signaling a leadership shift as the company continues its development pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sarepta's FDA decision date; Flare gets Anna Protopapas as CEO”
read at Endpoints ↗81 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that